Program
sigvotatug vedotin
Also written as “Sigvotatug Vedotin”.
In Pfizer’s pipeline, Integrin beta-6-directed antibody-drug conjugate
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Pfizer.
Furthest: phase 3, since Aug 21, 20234 company-led studies, 3 open or runningNext primary completion: Jun 16, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 43 open or running | phase 3since Aug 21, 2023 | May 12, 2020 | Jun 16, 2027phase 1 · NCT04389632 |
- Named in Pfizer’s own pipeline as
sigvotatug vedotin PF-08046047
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 12, 2020First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04389632 · 1,006 planned · United States, France, South Korea and more
- Aug 21, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06012435 · 762 enrolled · United States, Argentina, Australia and more
- Jul 22, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06549816 · 6 enrolled · China
- Dec 26, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06758401 · 714 planned · United States, Argentina, Australia and more
Ahead
- Jun 16, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT04389632
- Sep 5, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06758401
TargetBeta
“Integrin beta-6-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against integrin beta-6 (IB6) conjugated, via a protease-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic act…”NCIt, read by Claude
“Integrin beta-6 binding agent”ChEMBL 37, by rule
Other programs on ITGB6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876 | Pfizer | phase 1 | 1 |
| Anti-integrin Beta-6/MMAE Antibody-drug Conjugate PF-08052667 | Pfizer | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06758401Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Sep 5, 2028 | 714 |
| NCT06549816Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Nov 18, 2025 | 6 |
| NCT06012435Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 18, 2026 | 762 |
| NCT04389632Carcinoma, Non-Small-Cell Lung · United States, France, South Korea and more | 1 | Recruiting | Jun 16, 2027 | 1,006 |
How it is read
Names in the registry
- “sigvotatug vedotin”, 3 entries
- “Sigvotatug Vedotin”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.